Work

2029TiP Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2855

Authors: S. Chandana, B. Garmezy, A. Dowlati, M.R. Sharma, W. Henner, R. Robinson, P. Hingorani, E. Jeng, K.P. Papadopoulos

Institutions: Sarah Cannon, University Hospitals Seidman Cancer Center, AbbVie (United States), South Texas Accelerated Research Therapeutics

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: AbbVie

OpenAlex ID: W4387810209

FWCI: 0.599

Cites: 1

Cited by: 4

Related to: 10